Long Acting GLP-1 Receptor Agonists and Methods of Use
Summary
The European Patent Office published patent application EP4263587A1 for long-acting GLP-1 receptor agonists filed by I2O Therapeutics, Inc. The patent covers glucagon-like polypeptide-1 receptor agonist compositions and methods of use for treating metabolic disorders including obesity, hyperlipidemia, and diabetes. The patent is directed to peptide compounds classified under C07K 14/605 with designated protection across 31 European member states.
What changed
The EPO published patent application EP4263587A1 for long-acting GLP-1 receptor agonists, providing I2O Therapeutics exclusive rights to the claimed peptide compositions and treatment methods across European designated states including Germany, France, UK, Italy, Spain, and 27 other member nations.
Pharmaceutical and biotechnology companies developing GLP-1 based therapies must consider potential freedom-to-operate implications given this newly granted patent. Generic or biosimilar manufacturers seeking to enter the European metabolic disease market may need to evaluate licensing options or design-around strategies to avoid infringement on the protected peptide compositions and methods of use.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
LONG ACTING GLUCAGON LIKE POLYPEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND METHODS OF USE
Publication EP4263587A1 Kind: A1 Apr 08, 2026
Applicants
I2O Therapeutics, Inc.
Inventors
BLACKWELL, William, SRIVASTAVA, Ved P., PAULIK, Mark
IPC Classifications
C07K 14/605 20060101AFI20220624BHEP A61P 3/04 20060101ALI20220624BHEP A61P 3/06 20060101ALI20220624BHEP A61P 3/10 20060101ALI20220624BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.